Eli Lilly Unveils New Data on Obesity Treatment at ADA Meeting
At the American Diabetes Association's annual meeting, Eli Lilly shared new findings regarding the safety and tolerability of its obesity drug retatrutide.
Editorial Staff
1 min read
Updated 3 days ago
Eli Lilly recently presented updated safety and tolerability data for its next-generation obesity medication, retatrutide.
This information was shared during the annual meeting of the American Diabetes Association, highlighting the company's ongoing research efforts.
The findings may play a significant role in the future development and approval of retatrutide as a treatment option for obesity.